论文部分内容阅读
SARS-CoV-2 spike(S)glycoprotein is the key target of current vaccine development efforts to combat COVID-19;neutralizing antibodies bind S and interfere with S binding to its receptor,angiotensin-converting enzyme 2.Recent work reveals the molecular basis of increased infectivity of the globally prevailing D614G S mutation.